<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Sotalol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00489</strong>&#160; (APRD01230)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00489/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00489/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00489.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00489.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00489.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00489.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00489.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00489">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Sotalol</td><td>French/German/Spanish</td><td>INN</td></tr><tr><td>Sotalolo</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCIT</td></tr><tr><td>Sotalolum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Sotalol Hydrochloride</strong>
          <div class="cas">959-24-0</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000318/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000318/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: VIDRYROWYFWGSY-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 308.096140945</li>
              <li>Average Mass: 308.825</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000318">DBSALT000318</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Betapace</td><td>Berlex</td></tr><tr><td>Biosotal</td><td>Sanofi-Aventis</td></tr><tr><td>Cardol</td><td>Alphapharm</td></tr><tr><td>Darob</td><td>Abbott</td></tr><tr><td>Darob mite</td><td>Abbott</td></tr><tr><td>Hipecor</td><td>Merck</td></tr><tr><td>Loritmik</td><td>Krka</td></tr><tr><td>Rytmobeta</td><td>Abbott</td></tr><tr><td>Sorine</td><td>Upsher-Smith</td></tr><tr><td>Sotacor</td><td>Bristol-Myers Squibb</td></tr><tr><td>Sotagard</td><td>GlaxoSmithKline</td></tr><tr><td>Sotalex</td><td>Bristol-Myers Squibb</td></tr><tr><td>Sotapor</td><td>Bristol-Myers Squibb</td></tr><tr><td>Talozin</td><td>Adeka</td></tr><tr><td>Tan Shi</td><td>Chia Tai Tianqing</td></tr><tr><td>Xi An Lin</td><td>Changzhou Pharmaceutical Factory</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>3930-20-9</td></tr><tr><th>Weight</th><td>Average: 272.364<br>Monoisotopic: 272.119463206</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>S</td></tr><tr><th>InChI Key</th><td>ZBMZVLHSJCTVON-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-(4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}phenyl)methanesulfonamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Sulfanilides</td></tr><tr><th>Direct parent</th><td>Sulfanilides</td></tr><tr><th>Alternative parents</th><td>Sulfonyls; Sulfonamides; Secondary Alcohols; 1,2-Aminoalcohols; Dialkylamines; Polyamines</td></tr><tr><th>Substituents</th><td>sulfonyl; sulfonamide; sulfonic acid derivative; 1,2-aminoalcohol; secondary alcohol; secondary amine; secondary aliphatic amine; polyamine; alcohol; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Also for the treatment of documented life-threatening ventricular arrhythmias.</td></tr><tr><th>Pharmacodynamics</th><td>Sotalol is an antiarrhythmic drug. It falls into the class of beta blockers (and class II antiarrhythmic agents) because of its primary action on the &#946;-adrenergic receptors in the heart. In addition to its actions on the beta receptors in the heart, sotalol inhibits the inward potassium ion channels of the heart. In so doing, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity. It also slows atrioventricular (AV) nodal conduction. Because of these actions on the cardiac action potential, it is also considered a class III antiarrhythmic agent. The beta-blocking effect of sotalol is non-cardioselective, half maximal at about 80mg/day and maximal at doses between 320 and 640 mg/day. Sotalol does not have partial agonist or membrane stabilizing activity. Although significant beta-blockade occurs at oral doses as low as 25 mg, significant Class Ieffects are seen only at daily doses of 160 mg and above.</td></tr><tr><th>Mechanism of action</th><td>Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class I) and cardiac action potential duration prolongation (Vaughan Williams Class I) antiarrhythmic properties. Sotalol is a racemic mixture of d- and l-sotalol. Both isomers have similar Class I antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-blocking activity. Sotalol inhibits response to adrenergic stimuli by competitively blocking &#946;<sub>1</sub>-adrenergic receptors within the myocardium and &#946;<sub>2</sub>-adrenergic receptors within bronchial and vascular smooth muscle. The electrophysiologic effects of sotalol may be due to its selective inhibition of the rapidly activating component of the potassium channel involved in the repolarization of cardiac cells. The class II electrophysiologic effects are caused by an increase in sinus cycle length (slowed heart rate), decreased AV nodal conduction, and increased AV nodal refractoriness, while the class III electrophysiological effects include prolongation of the atrial and ventricular monophasic action potentials, and effective refractory period prolongation of atrial muscle, ventricular muscle, and atrio-ventricular accessory pathways (where present) in both the anterograde and retrograde directions. </td></tr><tr><th>Absorption</th><td>In healthy subjects, the oral bioavailability of sotalol is 90-100%. Absorption is reduced by approximately 20% compared to fasting when administered with a standard meal.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Sotalol does not bind to plasma proteins.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Sotalol is not metabolized.</p></td></tr><tr><th>Route of elimination</th><td>Excretion is predominantly via the kidney in the unchanged form. Sotalol is excreted in the milk of laboratory animals and has been reported to be present in human milk.</td></tr><tr><th>Half life</th><td>Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>The most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachy-cardia, and premature ventricular complexes.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.995</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6708</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8881</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9638</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9514</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7392</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8296</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6194</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8807</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8276</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.587
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9949
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2873 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.846
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8701
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Academic pharmaceuticals inc</li>
<li>Bayer healthcare pharmaceuticals inc</li>
<li>Upsher smith laboratories inc</li>
<li>Amneal pharmaceutical</li>
<li>Apotex inc</li>
<li>Apotex inc etobicoke site</li>
<li>Impax pharmaceuticals</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Vintage pharmaceuticals inc</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.amneal.com">Amneal Pharmaceuticals</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.bayerhealthcare.com">Bayer Healthcare</a></li>
<li><a href="http://www.bionichepharmausa.com">Bioniche Pharma</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Eon Labs</li>
<li>Genpharm LP</li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li><a href="http://www.gsms.us">Golden State Medical Supply Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Novopharm Ltd.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Promex Medical Inc.</li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li>
<li><a href="http://www.upsher-smith.com">Upsher Smith Laboratories</a></li>
<li>Vangard Labs Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00414">Acetohexamide</a></td><td>The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00672">Chlorpropamide</a></td><td>The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00575">Clonidine</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>The beta-blocker, sotalol, may increase the toxicity of disopyramide.</td></tr><tr><td><a href="/drugs/DB00668">Epinephrine</a></td><td>Hypertension, then bradycardia</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01288">Fenoterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB08868">Fingolimod</a></td><td>Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.</td></tr><tr><td><a href="/drugs/DB00983">Formoterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01044">Gatifloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01120">Gliclazide</a></td><td>The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00365">Grepafloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00047">Insulin Glargine</a></td><td>The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01137">Levofloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00968">Methyldopa</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00247">Methysergide</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00218">Moxifloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00816">Orciprenaline</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00236">Pipobroman</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00554">Piroxicam</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00457">Prazosin</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Possible additive effect on QT prolongation</td></tr><tr><td><a href="/drugs/DB00912">Repaglinide</a></td><td>The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB06402">Telavancin</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01162">Terazosin</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00871">Terbutaline</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. </td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>